#ASCO 2017 FATORES PROGNÓSTICO DO IMPACTO DE TUMOR BUDDING NO ESTUDO PROSPECTIVO SACURA TRIAL
Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2− Breast Cancer: KEYNOTE-756
Comentários
Postar um comentário